Pacira Non Current Assets Total from 2010 to 2024
| PCRX Stock | USD 30.33 0.13 0.43% |
Non Current Assets Total | First Reported 2009-12-31 | Previous Quarter 1.1 B | Current Value 1 B | Quarterly Volatility 401.4 M |
Check Pacira Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacira main balance sheet or income statement drivers, such as Depreciation And Amortization of 79.4 M, Interest Expense of 16.1 M or Selling General Administrative of 63.1 M, as well as many exotic indicators such as Price To Sales Ratio of 2.19, Dividend Yield of 0.0 or PTB Ratio of 1.7. Pacira financial statements analysis is a perfect complement when working with Pacira Pharmaceuticals Valuation or Volatility modules.
Pacira | Non Current Assets Total |
Latest Pacira Pharmaceuticals' Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of Pacira Pharmaceuticals over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Pacira Pharmaceuticals' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pacira Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
| Timeline |
Pacira Non Current Assets Total Regression Statistics
| Arithmetic Mean | 442,778,440 | |
| Geometric Mean | 222,150,002 | |
| Coefficient Of Variation | 105.10 | |
| Mean Deviation | 397,756,320 | |
| Median | 211,384,000 | |
| Standard Deviation | 465,378,545 | |
| Sample Variance | 216577.2T | |
| Range | 1.2B | |
| R-Value | 0.90 | |
| Mean Square Error | 44408.6T | |
| R-Squared | 0.81 | |
| Slope | 93,632,426 | |
| Total Sum of Squares | 3032080.7T |
Pacira Non Current Assets Total History
About Pacira Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Pacira Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Pacira Pharmaceuticals investors use historical funamental indicators, such as Pacira Pharmaceuticals's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Pacira Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Pacira Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pacira Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Pacira Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Pacira Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Assets Total | 1.1 B | 1.1 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pacira Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacira Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacira Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacira Pharmaceuticals Stock:Check out the analysis of Pacira Pharmaceuticals Correlation against competitors. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Pacira Stock analysis
When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.291 | Earnings Share 1.51 | Revenue Per Share 14.706 | Quarterly Revenue Growth 0.042 | Return On Assets 0.0376 |
The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.